乳腺癌组织中表皮生长因子受体（EGFR）的研究  

Epidermal Growth Factor Receptor Assay in Human Brest Cancer Tissue

作　　者：丁秀敏[1,2] 何振祥[1,2] 郎义方 石磊垣[1,2] 

机构地区：[1]天津市肿瘤研究所 [2]天津市肿瘤医院乳腺科

出　　处：《中国肿瘤临床》1995年第12期872-875,共4页Chinese Journal of Clinical Oncology

摘　　要：用￣（１２５）Ｉ标记的表皮生长因子（￣（１２５）Ｉ－ＥＧＦ）作为配基，用标准的ＥＧＦ作为竞争剂，采用单点饱和分析法测定了３６例乳腺癌组织中的ＥＧＦＲ含量，范围在１～１２２ｆｍｏｌ／ｍｇ膜蛋白之间，以１０ｆｍｏｌ／ｍｇ膜蛋白以上为阳性，乳腺癌阳性率为３８％。按乳腺癌临床分期的结果表明，临床分期越高，阳性率也越高。有淋巴结转移者较无淋巴结转移的病人阳性率有增高趋势。证明表皮生长因子受体与乳腺癌的恶性程度有关，但癌各组织学类型之间阳性率未见差别。Content of epidermal growth factor receptor(EUFR) was assayed using a standardized radioligand binding assay in 36 human primary breast cancer specimens and 4 benign tumor tissues.The value of≥10fmol/mg membrane proteinwas taken as the standard of positivity.Of the 36 specimens,14(38%)were EGFR(+)and 22(62%)EGFR(-).None of benign tumors of the breast was positive. There was statistical significance between EGFR positivity of specimens in clinical stages of Ⅰ-Ⅱ and Ⅲ-Ⅳ .An increased percentage of EGFR positivity was observed in patients with lymph node metastasis.

关 键 词：乳腺癌 表皮生长因子 受体 

分 类 号：R737.902[医药卫生—肿瘤] R730.21[医药卫生—临床医学]